CHR-2797

DRUG3 trials

Sponsors

Chroma Therapeutics, CTI BioPharma

Conditions

Acute Myeloid LeukemiaHealthySolid Tumor

Phase 1

A Study of the Safety and Tolerability of the Addition of CHR-2797 to Paclitaxel in Patients With Advanced or Refractory Tumours

CompletedNCT00737555

Chroma TherapeuticsSolid Tumor

Start: 2006-08-31End: 2008-03-31Updated: 2012-02-15

Crossover Trial of the Effect of a High-Fat Meal on the PK of Oral CHR 2797 in Healthy Male Subjects

CompletedNCT01638442

CTI BioPharmaHealthy

Start: 2012-06-30End: 2012-09-30Updated: 2023-09-18

Phase 2

Extension Study With Tosedostat in Relapsed/Refractory Acute Myeloid Leukemia

Chroma TherapeuticsAcute Myeloid Leukemia

Start: 2010-06-30End: 2013-06-30Target: 30Updated: 2012-02-15